These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38093366)

  • 21. Lecanemab in Early Alzheimer's Disease.
    van Dyck CH; Swanson CJ; Aisen P; Bateman RJ; Chen C; Gee M; Kanekiyo M; Li D; Reyderman L; Cohen S; Froelich L; Katayama S; Sabbagh M; Vellas B; Watson D; Dhadda S; Irizarry M; Kramer LD; Iwatsubo T
    N Engl J Med; 2023 Jan; 388(1):9-21. PubMed ID: 36449413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
    Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
    Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Latrepirdine for Alzheimer's disease.
    Chau S; Herrmann N; Ruthirakuhan MT; Chen JJ; Lanctôt KL
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD009524. PubMed ID: 25897825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease.
    Henderson ST; Morimoto BH; Cummings JL; Farlow MR; Walker J
    J Alzheimers Dis; 2020; 75(2):547-557. PubMed ID: 32310169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
    Grossberg GT; Manes F; Allegri RF; Gutiérrez-Robledo LM; Gloger S; Xie L; Jia XD; Pejović V; Miller ML; Perhach JL; Graham SM
    CNS Drugs; 2013 Jun; 27(6):469-78. PubMed ID: 23733403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4
    Xu Q; Zhang Y; Zhang X; Liu L; Zhou B; Mo R; Li Y; Li H; Li F; Tao Y; Liu Y; Xue C
    Clin Nutr; 2020 Jul; 39(7):2092-2105. PubMed ID: 31694759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.
    Bae CY; Cho CY; Cho K; Hoon Oh B; Choi KG; Lee HS; Jung SP; Kim DH; Lee S; Choi GD; Cho H; Lee H
    J Am Geriatr Soc; 2000 Dec; 48(12):1566-71. PubMed ID: 11129744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
    Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
    Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial.
    Jia Y; Zhang X; Yu J; Han J; Yu T; Shi J; Zhao L; Nie K
    BMC Complement Altern Med; 2017 Dec; 17(1):556. PubMed ID: 29284465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
    Schwam EM; Nicholas T; Chew R; Billing CB; Davidson W; Ambrose D; Altstiel LD
    Curr Alzheimer Res; 2014; 11(5):413-21. PubMed ID: 24801218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
    Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
    Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
    Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
    Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
    J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.
    Quinn JF; Raman R; Thomas RG; Yurko-Mauro K; Nelson EB; Van Dyck C; Galvin JE; Emond J; Jack CR; Weiner M; Shinto L; Aisen PS
    JAMA; 2010 Nov; 304(17):1903-11. PubMed ID: 21045096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.